Drugs / MRx0518
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04193904 | Dec 2019 → May 2023 | malignant pancreatic neoplasm | 4D pharma plc | Terminated | No outcome recorded |
| Phase 1 | NCT03934827 | Apr 2019 → Dec 2022 | breast cancer, head and neck cancer, kidney cancer, lung cancer +6 | Imperial College London | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03637803 | Jan 2019 → May 2023 | melanoma, non-small cell lung carcinoma, renal cell carcinoma, urinary bladder cancer | 4D pharma plc | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05107427 | Mar 2022 → Apr 2023 | urothelial carcinoma | 4D pharma plc | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRx0518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03637803 ↗ |
| Modality | Other / unclassified | “MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium.” NCT03637803 ↗ |
| Route | Oral | “one capsule orally twice daily for 2-4 weeks until surgery” NCT03934827 ↗ |